Concerns have been raised by Australia, the US, and the UK regarding counterfeit batches of the Abhayrab rabies vaccine circulating in India since late 2023. While the manufacturer, Indian Immunologicals Limited (IIL), asserts the vaccine itself is genuine and the issue is resolved, foreign health authorities warn individuals vaccinated in India may not be fully protected. Experts highlight potential cold chain breaches and India's significant rabies burden, while IIL calls the international response overcautious.